Andrew Brunner, MD

• Acute Myeloid Leukemia
• Myelodysplastic syndrome
• Acute Lymphocytic Leukemia

Myelodysplastic syndromes are disorders of the bone marrow associated with bone marrow failure and a risk of progression to acute myeloid leukemia. My clinical area of focus and research projects are focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. The therapies available for patients with MDS have not changed in the last decade, and there is critical need to develop new agents and identify the patients most likely to benefit from a given chemotherapy. I am involved in clinical trials for all stages of MDS with an overall goal of tailoring treatment to improve the outcomes of these patients.